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Abstract
We describe the basic tenets of the current concepts of cancer biology, and review the recent advances
on the suppressor role of senescence in tumor growth and the breakdown of this barrier during the origin
of tumor growth. Senescence phenotype can be induced by (1) telomere attrition-induced senescence at
the end of the cellular mitotic life span (MLS*) and (2) also by replication history-independent, accelerated
senescence due to inadvertent activation of oncogenes or by exposure of cells to genotoxins. Tumor
suppressor genes p53/pRB/p16INK4A and related senescence checkpoints are involved in effecting the
onset of senescence. However, senescence as a tumor suppressor mechanism is a leaky process and
senescent cells with mutations or epimutations in these genes escape mitotic catastrophe-induced cell
death by becoming polyploid cells. These polyploid giant cells, before they die, give rise to several cells
with viable genomes via nuclear budding and asymmetric cytokinesis. This mode of cell division has been
termed neosis and the immediate neotic offspring the Raju cells. The latter inherit genomic instability and
transiently display stem cell properties in that they differentiate into tumor cells and display extended, but,
limited MLS, at the end of which they enter senescent phase and can undergo secondary/tertiary neosis to
produce the next generation of Raju cells. Neosis is repeated several times during tumor growth in a non-
synchronized fashion, is the mode of origin of resistant tumor growth and contributes to tumor cell
heterogeneity and continuity. The main event during neosis appears to be the production of mitotically
viable daughter genome after epigenetic modulation from the non-viable polyploid genome of neosis
mother cell (NMC). This leads to the growth of resistant tumor cells. Since during neosis, spindle
checkpoint is not activated, this may give rise to aneuploidy. Thus, tumor cells also are destined to die due
to senescence, but may escape senescence due to mutations or epimutations in the senescent checkpoint
pathway. A historical review of neosis-like events is presented and implications of neosis in relation to the
current dogmas of cancer biology are discussed. Genesis and repetitive re-genesis of Raju cells with
transient "stemness" via neosis are of vital importance to the origin and continuous growth of tumors, a
process that appears to be common to all types of tumors. We suggest that unlike current anti-mitotic
therapy of cancers, anti-neotic therapy would not cause undesirable side effects. We propose a rational
hypothesis for the origin and progression of tumors in which neosis plays a major role in the multistep
carcinogenesis in different types of cancers. We define cancers as a single disease of uncontrolled neosis
due to failure of senescent checkpoint controls.
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Background
Mitosis and meiosis are the classic modes of cell division,
which have engaged the attention of the scientists for
more than a century. While mitosis involves the symmet-
ric division of a diploid, somatic cell to yield two diploid
daughter cells identical to the mother cell, meiosis or
reduction division yields varying number of haploid
daughter cells with chromosomes carrying new combina-
tions of alleles due to the cross-over phenomena. While
the former is responsible for the somatic growth of multi-
cellular organisms from the single celled zygote, the later
is involved in sexual reproduction by producing oocytes
or sperms, which will reconstitute the diploid somatic
cells after fertilization. In both cases, the nuclear envelope
is disassembled to facilitate accurate chromosome distri-
bution during karyokinesis, and is reassembled at the end
of kayrokinesis during the telophase [1]. Errors in chro-
mosome segregation during mitosis may cause aneu-
ploidy, which will be detrimental to the cell and if viable,
the cell will gain genomic instability, possibly leading to
cancer growth. In order to assure that the somatic cells
faithfully duplicate and distribute the genomic DNA to
daughter cells with high fidelity, several checkpoint con-
trols have evolved to regulate the mitotic cell cycle pro-
gression in order to maintain genomic stability in
daughter cells [Reviewed in [2-4]]. In addition, cells have
evolved tumor suppressor program consisting of tumor
suppressor genes and apoptosis genes.
Recently, the role of senescence as a tumor suppressor
program has been demonstrated both in vitro and in vivo,
which is considered to be as efficient as the apoptosis pro-
gram. Cellular senescence can set in under different cir-
cumstances, which fall into two major categories: (1)
replication history-dependent telomere attrition-induced
senescence and (2) replication history-independent
senescence. Senescence phenotype induced by exposure
to chemotherapeutic agents fall in the second category.
These agents induce accelerated senescence in both nor-
mal and tumor cells. Cellular events linking accelerated
senescence to mitotic arrest and cell death via mitotic
catastrophe, and eventual out growth of aneuploid neo-
plastic cells from such senescent populations have not
been clearly understood. In this review, (1) we summarize
the current concepts of cancer self-renewal, (2) draw
attention to recent developments in the understanding of
the role of senescence in cancer and (3) describe the novel
mode of cell division termed neosis, which helps cells
bypass senescence and aids tumor growth [5,6]. Further,
we discuss the implications of these findings to the cur-
rent concepts of cancer biology and propose a neosis-
based multistep carcinogenesis hypothesis that provides a
more rational explanation of the steps involved in the ori-
gin and progression of tumors.
Current concepts in cancer biology
The essentials of the current concepts of cancer growth are
three fold: (1) Cancer originates via mitotic division of
normal cells with DNA damage [7]; (2) Cancer cells orig-
inate from mutant stem cells called cancer stem cells
(CSCs), which have the potential to self-propagate by
asymmetric division yielding one CSC and one differenti-
ating into tissue-specific tumor cell; [8-14] and (3) since
CSCs retain the properties of stem cells, they are immortal
and have unlimited division potential without being sub-
jected to the phenomenon of aging. Emerging new evi-
dence hints at a major revision of these current concepts
about cancer.
Mitosis and cancer
Current concept of cancer is based on the belief that
tumor cells arise after about 13 mitotic divisions of the
initiated cell [7]. In addition, cancer cells also multiply by
mitotic division. Therefore, the conventional non-surgical
cancer treatments, consisting of chemotherapy and radio-
therapy target only the mitotic populations of tumor cells.
They do not differentiate between proliferating normal
and tumor cells. This results in undesirable side effects
that limit the level of usable dose-intensity of these treat-
ments and restrict their application to only the fittest of
patients, this approach results in the growth of resistant
tumor cells in the place of originally responsive tumor
often in a matter of months by a mechanism that has not
been clearly understood. Development of novel strategies
to improve current status of cancer therapy will require
identification and exploitation of yet unrecognized differ-
ences between normal and tumor cells with respect to
propagation, evolution and development of resistance to
conventional treatments [15,16].
Immortality of cancer cells and limited mitotic life span of 
diploid somatic cells
The common belief that cancer cells are immortal proba-
bly originated from the early attempts at mammalian cell
culture in vitro. Gey et al. [17] grew normal epithelial cells
and also cultured cells from invasive colon carcinoma.
They established one of the oldest cancer cell cultures,
HeLa cells with continuous division potential. This
resulted in the notion that cells are immortal, while the
whole organisms were mortal.
With the advent of sterile culture conditions and
improved culture media, Hayflick published his well
known study on normal embryonic diploid human lung
fibroblasts. Hayflick suggested that there was a "finite
limit to the cultivation period of diploid cell strains" and
that this was "attributable to the intrinsic factors which are
expressed as senescence at the cellular level," while trans-
formed or cancer cells were capable of unlimited mitotic
division potential and, therefore, were consideredCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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'immortal' [18]. It has been now well established that this
Hayflick limit and the phenomenon of senescence are due
to the limited mitotic division potential of normal human
somatic cells. At the end of their limited mitotic life span
(MLS), normal cells enter a permanent non-proliferative
senescence phase, characterized by a large, flat morphol-
ogy, a high frequency of nuclear abnormalities and often
consisted of multinucleate and/or polyploid giant cells
(MN/PG cells). Senescent cells display positive stain for
senescence associated β-galactosidase at pH 6.0 (SA-β-gal)
[19]. Such cells display mitotic crisis and are thought to
die by mitotic catastrophe [20]. Onset of replicative senes-
cence in human cells is caused by the exhaustion of
mitotic potential due to telomere attrition as a function of
aging [21-23]. Telomere shortening beyond a certain limit
triggers DNA damage response [24-26].
Stem cells and their asymmetric division potential
Stem cells are characterized by (1) the potential to
undergo continuous self-renewal and extensive prolifera-
tion, (2) the maintenance of a constant pool of the undif-
ferentiated stem cells through the life time of the host and
(3) the potential to undergo differentiation into multiple
cell types upon receiving the appropriate stimulus from
the microenvironment. The primordial stem cell is the fer-
tilized oocyte or zygote, which gives rise to embryonic,
germinal and adult stem cells during development.
Embryonic stem cells (ESCs) isolated from the inner cell
mass of 5–6 day old mammalian embryos are able to dif-
ferentiate into different cell types derived from all three
germ layers and are, therefore, considered pluripotent;
ESCs undergo symmetric and logarithmic expansion by
mitosis, both daughter cells being identical and retaining
pluripotency. Germinal stem cells (GSCs) are confined to
the gonads. After mitotic amplification, followed by a ter-
minal meiotic division, they produce the egg or the sperm
for sexual reproduction. During the early embryonic
development, as the germ layers are formed from the
ESCs, the process of cellular determination and organo-
genesis are initiated. The stem cells begin to undergo
asymmetric mitotic division, where one daughter cell
maintains the stem cell pool specific for different organs
and tissues, and the other starts the process of differentia-
tion through transit amplifying stages and becomes the
progenitor of somatic cells. These are the adult stem cells
(ASCs) or resident tissue-specific stem cells that are
involved in tissue homeostasis and are capable of tissue
regeneration. Thus, during development, the ESCs eventu-
ally give rise to about 200 different cell types of the adult
organism, as would be expected of their pluripotency
[6,27].
Stem cells and Cancer Stem Cells (CSCs)
Studies on the susceptibility of fish and mammalian
embryos to tumorigenecity by carcinogens showed that
early embryos in vivo were resistant to carcinogenic agents.
They became increasingly susceptible to tumorigenic
mutations by carcinogens, after the development of tissue
specific adult stem cells or ASCs and the process of orga-
nogenesis was initiated [28-31] The following two differ-
ent conclusions can be drawn from these data [6]:
(1) Adult stem cells were prone to tumorigenic mutations,
while the transit amplifying and differentiating cells were
not and the embryonic stem cells were also resistant to
tumorigenic mutations due to their innate nature;
(2) Determined adult stem cells (ASCs) and their commit-
ted transit amplifying cells and derivatives on the way to
differentiation were highly susceptible to tumor initiating
mutations, while the embryonic stem cells were relatively
resistant.
By this time, the Hayflick's concept of normal somatic
cells had limited mitotic division potential [18] and the
concept of 'immortality' of tumor cells [17] were well
known. It was also demonstrated that stem cells with
some mutation might play a role in the clonal origin of
some cancers [30-32]. The concept of stem cell origin of
cancers was postulated during the later part of the 19th
century [14]. The first experimental proof was published
by Till and McCullach [33]. Based on teratocarcinoma
studies, Pierce [34] proposed that cancer was due to mat-
uration arrest of stem cells. Thus, the scientific atmos-
phere was ripe to interpret these data on embryonic
carcinogenesis induction [30,31,35] to mean that stem
cells (ASCs) in regenerating tissues could be susceptible to
epigenetic changes, while they still retained their unlim-
ited division potential and, therefore, immortality. The
proposal that transformation of normal cells into neo-
plastic cells with unlimited mitotic division potential was
due to genetic and epigenetic alterations in ASCs, with the
retention of their unlimited division potential [30,31,35]
seemed a reasonable assumption. Thus, the suggestion
that mutant ASCs formed during the regenerative stages
gave rise to mutant stem cells, and have retained their
unlimited division potential was generally accepted.
Based on the striking similarities between the ASCs and
cancer cells, the 'immortality' of cancer cells has been
attributed to a minority of tumor cells that can not only
self-renew but also can give rise to a full fledged tumor tis-
sue consisting of stem-like cells and abnormally differen-
tiated cells, thus resulting in the hierarchical nature of
tumor cell population [36,37]. These events lead to the
formation of a cell mass consisting of a minor percentage
of cancer stem cells, proliferating progenitor tumor cells
and non-dividing, incompletely differentiated tumor cells
making up the bulk of the tumor tissue. Thus, the concept
that cancer is a disease of unlimited mitotic division has
gained acceptance and the tumor-initiating cancer cellsCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
Page 4 of 26
(page number not for citation purposes)
with self-renewal potential have been termed "Cancer
Stem Cells" (CSCs). Therefore, akin to the ASCs, CSCs are
thought to constitute a constant pool of mutated adult
stem cells, and by virtue of their asymmetric division
potential, are responsible for the continuous growth of
tumor tissue, that consists of CSCs and differentiated
tumor cells [8,13,14,37].
The concept that resident adult tissue stem cells turn into
CSCs with their own specific surface markers has gained
wide acceptance. Stem cell origin of cancers has been rec-
ognized in hematopoietic malignancies decades ago
[8,14,33,38,39] and more recently in solid tumors such as
breast tumors, brain tumors [9-13], melanoma [40] and
prostate cancer [41], each having its own specific surface
markers. The identification of such CSCs as a target for
anti-tumor therapy is currently being actively investigated
with the aim of using them as specific targets for cancer
therapy [11-13]. However, this concept is still controver-
sial and implies, but has not yet been unequivocally
proven, that CSCs are capable of asymmetric division, i.e.,
one daughter cell maintaining the CSC pool and the other
differentiating into tumor cells [6,42-44]. Recently, the
theoretical and technical difficulties of the CSC hypothe-
sis have been reported [42]. In addition, it is likely that
such tissue specific CSC markers are not unique to CSCs,
but may also be shared by normal stem cells and, proba-
bly, to a lesser degree by their transit amplifying somatic
cell intermediates. Further, since the CSCs are thought to
be immortal, this, in turn, implies that they are not subject
to aging and senescence, which will inevitably lead to tel-
omere attrition due to senescence-checkpoint and rejuve-
nation via neosis to turn cancerous (6, Also see below).
Stem cells (ASCs) resemble somatic cells
Weismann [45] popularized the concept of a complete
separation in metazoans between a potentially immortal
germ line and a mortal soma that transfers the germ line
to the next generation and then senesces. This concept has
led to the conviction that somatic cells are subject to
senescence, while the germ cells are not. However, it
should be pointed out that even the germ cells are also
subject to aging along with its host [46]; however, they are
rejuvenated by sexual reproduction at the beginning of
each generation. According to this definition, adult stem
cells would also be considered to be somatic cells, since
these are probably committed to differentiate, although
they might be more primitive compared to transit ampli-
fying cells [6,27].
In spite of the obvious difference in the division potentials
between ASCs (potential to self-renew and unlimited
MLS) and differentiating somatic cells (limited MLS), it is
becoming increasingly clear that ASCs may lose division
potential as they approach their differentiated state, and
share several properties of the transit amplifying and dif-
ferentiating cells. These include: (1) responsiveness of
ASCs to both intracellular and extracellular factors to stop
cycling and enter differentiation pathways or to enter
cycling state and play a role in tissue homeostasis [27,47];
(2) an age-dependent decrease of telomere length in
human hematopoietic stem cells (hHSCs), probably con-
tributing to a reduction in their proliferation potential
[48,49]; (3) limited division potential of adult human
mesenchymal stem cells (hMSCs) in vitro that can differ-
entiate into multiple cell lineages including bone, carti-
lage, adipose and muscle tissues, due to a lack of
telomerase [50-52]; (4) the loss of tumor suppressor func-
tion of p16Ink4a/p14Arf (or senescence checkpoint con-
trols) confers 'immortality' to hMSCs; (5) extension of
population doubling of hMSC by transduction of the tel-
omerase gene hTERT in vitro; and (6) the emergence of
some sublines of the cells with extended MLS, loss of con-
tact inhibition, anchorage independent growth potential
and formation of mesenchymal tumors in 10/10 mice by
acquired loss of p16Ink4a/p21, due to epigenetic inactiva-
tion by methylation of DBCCRI gene purportedly
involved in the onset of senescence [53]
Conditional telomerase expression caused proliferation
of hair follicle stem cells in vivo [54], while overexpression
of mTERT in basal keratinocytes resulted in increased epi-
dermal tumors and increased wound healing in transgenic
mice in vivo [55]. These events are similar to the events
after telomerase transduction in non-stem somatic cell
populations, respectively [6,21-23,48,56-63]. In addition,
telomerase is required for retarding the shortening of tel-
omeres and to extend the replicative life span of HSCs
during serial transplantation [64]. Expression of hTERT in
HIV-specific CD8+ T cells showed both an enhanced and
sustained capacity to inhibit HIV-1 replication and
enhanced antiviral functions accompanied by an increase
in proliferative potential and telomere length stabiliza-
tion [65]. As in the case of somatic differentiating cells,
stem cells also undergo telomere attrition during aging,
which is followed by breakage-fusion-bridge cycle, giving
rise to self-propagating mechanism for increasing the level
of genomic instability via aneuploidy [48,52,63,65-67].
Stem cells are attractive candidates to initiate cancer due
to their pre-existing capacity for self-renewal and 'unlim-
ited' proliferative potential, and their likelihood of accu-
mulating mutations through the age of the host [14,47].
However, cancer causing mutations also arise in the more
committed progenitors, the mitotic derivatives of stem
cells at any state in the differentiation pathways in various
tissue cell types [8,68,69]. In fact, most of the in vitro stud-
ies since 1970s on cancer initiation, promotion, and pro-
gression have been carried out not in stem cells, but in
differentiating somatic, non-stem cells such as fibroblasts,Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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epithelial cells, myoblasts, chondrocytes etc., of various
mammalian species including mouse, rat, hamsters and
humans; and the resultant transformed cells isolated
using the transformed focus assay do form tumors in the
appropriate hosts [5,70-73]. Consistent with the concept
of origin of tumor growth from the differentiating popu-
lation beyond the initiation of determination stage is the
fact that almost ~200 different types of human cancers are
known, just as many as the number of differentiated cell
types [27]. This correlates well with ~200 different micro-
RNAs that are known to be involved in the process of dif-
ferentiation [74-76]. Recent findings that the microRNA
profiles of cancer cells reflect the developmental lineage
and differentiation stage of tumors [77] suggest that ASCs
and the transit amplifying cells and not simply the
'immortal' ASCs alone are prone to carcinogenic muta-
tions. Even differentiated cells may be prone to turn carci-
nogenic, when infected with tumor viruses such as acute
transforming viruses (Eg. RSV), Human T cell leukemia
virus, SV40, human papilloma viruses HPV-5, -8, -16, -18
and -31, human hepatitis virus B, and Burkitt's lymphoma
virus etc., since these viruses carry their own transforming
genes, that have potential to inactivate the tumor suppres-
sor genes required for the onset of senescence and often
carry growth promoting genes [78].
Senescence as a tumor suppressor mechanism
Since senescent cells do not respond to growth factors,
and display terminal mitotic crisis, the phenomenon of
senescence is thought to constitute a tumor suppressor
program [79-81] and is considered equivalent to the pro-
grammed cell death by apoptosis [82]. The relevance of
senescence as a tumor suppressor mechanism has been
recently demonstrated unequivocally in different tumor
systems in vitro and in vivo [81,83] and constitutes a fail-
safe, although not perfect, mechanism to inhibit cancer
growth.
While senescent cells do not enter the mitotic cycle even
in the presence of growth factors, they are alive and
remain metabolically active in culture for several years
[84]. This cell cycle arrest is due to the tumor suppressor
action of the genes involved in the p53/pRb/p16Ink4
pathway collectively termed the senescence checkpoint
control. Abrogation of this pathway by mutation, epige-
netic mechanisms or viral inactivation of any one of these
genes bypasses senescence checkpoint and the cells grow
beyond their normal intrinsic MLS. After an additional 20
– 30 population doublings, the cells enter a terminal
mitotic crisis. During this second mitotic crisis period the
cells display apoptotic death due to gross chromosomal
abnormalities, some rare cells continue to proliferate
yielding an 'immortal' cell line, by an unknown mecha-
nism. These two mitotic crisis phases in the normal cell
life span have been termed M1 and M2 [58,85].
Accelerated premature senescence in the absence of tel-
omere attrition can be induced by different non-lethal
conditions that cause acute genetic duress in primary cells
in vitro and in vivo. Such cells also display similar charac-
teristics such as non-responsiveness to growth factors,
large, flat cell morphology with nuclear abnormalities,
and stain positive for SA-β-gal and senescence associated
heterochromatin formation (SAHF) [Reviewed in
[19,84]]. DNA-damage induced repair response is acti-
vated in such cells, just as in the case of telomere attrition-
induced senescent cells. Such acute genetic stress-inducing
factors include unfavorable culture conditions [86], or the
addition of aberrant oncogenic and mitogenic signals
such as activated H-RAS [87]. In addition, as can be
expected, chemotherapeutic agents that induce DNA dou-
ble strand breaks [88], and mitotic spindle toxins [89,90]
are also known to effect accelerated senescent phenotype.
Oncogene-induced premature senescence will terminate a
pre-malignant condition before a fully transformed cell
can develop from primary cells [80,91] and is associated
with the p53, p16INK4a, pRB pathway. Using a mouse
model, in which the oncogene Ras was activated in the
hematopoietic cells of the bone marrow, Braig et al. [92]
have demonstrated that cellular senescence phenotype
can efficiently block the development of lymphoma. pRB-
mediated silencing of growth promoting genes by SAHF
was shown to be formed via methylation of histone H3
lysine 9 (H3K9me) [93]. The histone methyltransfearse
Suv39h1 protein methylates histones and physically
binds with pRB tumor suppressor protein [94,95].
Suv39h1 was shown to be required for oncogene-induced
premature senescence due to the introduction of Ras in
lymphocytes [92]. Proliferation of primary lymphocytes
was stalled by a SuV39h1-dependent H3Kme-related
senescent growth arrest in response to oncogenic Ras,
resulting in the inhibition of the initial step of lymphom-
agenesis. In Suv39h1-deficient lymphomas, RB was una-
ble to promote senescence [92]. Similarly, using
conditional oncogene K-rasV12  in a mouse model for
human cancer initiation, Collada et al. [96] have shown
that both in lung and in pancreas, premalignant tumor tis-
sues displayed extensive senescent cells as indicated by the
expression of different senescent markers including
p16INK4a, p15INK4b, SA-β-gal, Dec1, DcR2 and SAHF,
while these markers were rare or absent in the same
tumors after they turned malignant; this could prove use-
ful both in prognoss and diagnosis of cancer. Similarly,
chemically induced premalignant skin papillomas with
H-Ras oncogenic mutation displayed senescence marker
in vivo [96].
Inactivation of the tumor suppressor PTEN (a lipid phos-
phatase that negatively regulates PI3 Kinase-AKT/PKB sur-
vival pathway) produces hyperplasticity in mice prostateCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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epithelial cells similar to precancerous lesions in human
prostate epithelium. Expression of senescence markers
was reported [97] in these lesions, which was associated
with inhibition of the development of malignancy.
Absence of p53 prevents the senescence response to loss
of PTEN and loss of both p53 and PTEN leads to invasive
prostate carcinoma in mice [97]. In another study, using a
conditional transgenic model with the mitogenic E2F3
transcription factor, Denchi et al., [98] have shown that
E2F3 expression induced a burst of initial pituitary hyper-
plasia followed by a cessation of cell proliferation accom-
panied by expression of senescence markers. Michaloglou
et al., [99] have reported that in cultures of human
melanocytes and naevi, the benign precursors of malig-
nant melanoma, an oncogenic allele BRAF, a protein
kinase downstream of Ras, derived from human melano-
mas can induce sustained cell cycle arrest and senescence
in fibroblasts and melanocytes, accompanied by the
expression of p16INK4a and the common senescence
marker, SA-β-gal. Congenital naevi in vivo were invariably
positive for both SA-β-gal and spotty induction of
p16INK4a expression, indicating that factors other than
p16INK4a may cooperate with the mutant BRAF in bring-
ing about senescence phenotype. The senescence pheno-
type was not brought about by telomere attrition,
supporting the fact that oncogene-induced senescence is a
genuine case of protective physiological process. After an
initial cell proliferation, which results in the formation of
naevi, such lesions typically remain static and benign.
Loss of Ku86 involved in chromosomal metabolism
induces early onset of senescence in mice [100]. Telomere
fusions responsible for breakage fusion bridge formation
can be caused by mutations in the terminal region of tel-
omeric DNA [101,102]. It has been recently shown that
psychological stress, both perceived and chronic, is signif-
icantly associated with higher oxidative stress, lower tel-
omerase activity, and shorter telomere length, which are
known determinants of cell senescence and longevity, in
peripheral blood mononuclear cells from healthy pre-
menopausal women [103]
In general, the senescence checkpoint pathway genes such
as MAPK [104,105], and overexpression of p53 [reviewed
in [106]] and the genes that regulate p53 including ARF
(p14ARF in human or p19ARF in mice), p33ING1 [107],
PML [108-110], nucleoplasmin or NPM [111] and PTEN
[97] are all involved in the senescence-induced tumor
suppression program [Reviewed in [19,84]].
The above studies indicate that an initial burst of cell divi-
sion due to activation of an oncogene expression in pri-
mary diploid cells results in the formation of
premalignant tumor growth arrest with senescent mor-
phology, and such lesions often remain benign without
any further proliferation, until it progresses to a malignant
state by additional mutations [112] and epimutations.
This type of senescent phenotype appears to be caused by
a telomere attrition-independent or proliferative history-
independent mechanism and is termed premature or
accelerated senescence which is likely to be favored by the
absence of telomerase in somatic cells. However, cell types
which maintain telomere length due to endogenous tel-
omerase activity also display a senescent phenotype in
vitro. An example is rodent fibroblasts with long telomeres
and telomerase expression that can be induced to undergo
premature senescence due to culture conditions [85] or
after exposure to genotoxins [5]. Human epithelial cells
when grown on plastic will undergo senescence, but,
when cultured on a feeder layer, they proliferate indefi-
nitely without any sign of senescence [113]. These data
demonstrate that even in the absence of intrinsic mecha-
nism of limited life span due to telomerase expression,
such cells will respond to extrinsic factor(s)-induced
cumulative damage to DNA by entering premature senes-
cence phase.
Induction of accelerated senescence as anti-cancer 
therapy
It is clear that the senescence phenotype can be induced
under different conditions that might cause impediment
to normal mitosis creating a mitotic crisis, including: (1)
intrinsic ageing induced senescence (M1); (2) prolifera-
tive history dependent telomere attrition induced mitotic
crisis (M2); (3) spontaneous, cumulative DNA damage
induced senescence; (4) oncogene-induced accelerated
senescence; and (5) genotoxin-induced premature senes-
cence.
As described above, in primary cells, induction of an
accelerated senescent phase acts as an efficient tumor sup-
pressor mechanism; and DNA damaging agents or geno-
toxins also elicit an accelerated senescence-like phenotype
[Reviewed in [114-116]] by activating DNA damage
response pathways [88]. Tumor cells in vivo also display
the phenomenon of senescence in response to exposure to
genotoxins [reviewed in [19,84]]. Such cells may either
undergo cytostasis and may never undergo mitosis again,
even in the presence of growth factors, or they may die via
apoptoss or mitotic catastrophe, Some cells may escape
senescence and give rise to resistant tumor growth. (See
Fig. 1 for the possible different fates of cells after exposure
to genotoxins.)
Since senescence appears to be a tumor suppressor mech-
anism, it appears attractive to induce senescence in
tumors in vivo in order to create a cytostatic state, where
the tumor may not be completely eliminated, but can be
maintained in a 'harmless' (non-proliferative) state
[19,84]. This approach is especially attractive, since initia-Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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Fate of cells exposed to genotoxins: Immediate effect of exposure to genotoxins is the arrest of cell cycle progression Figure 1
Fate of cells exposed to genotoxins: Immediate effect of exposure to genotoxins is the arrest of cell cycle progression. Cells 
with lethal damage will undergo necrotic death immediately or may commit immediate or delayed suicide by programmed cell 
death or apoptosis. Adaptation I. Some cells with minimal damage may re-enter cell cycle after some delay and repair of dam-
age, and multiply normally without any immediate phenotypic changes. It is likely that some of these cells may carry epigenetic 
alterations and undergo neosis after a latent period of accumulation of additional damage to the genome. Adaptation Ii. Some 
cells become tetraploid due to cytokinesis failure. Some of them may commit apoptosis, or undergo mitotic catastrophe due to 
active mitotic checkpoint; such cells often form micronuclei during death. Some of them may undergo successfully multipolar 
mitosis, giving rise to aneuploid cells, which may not survive to give rise to clonal population of tumor cells. Adaptation III. A 
major fraction of cells enter a premature senescent phase due to genotoxin-induced DNA damage; by about a week or so, 
they express senescent markers such as SA-β-gal and SAHF in order to suppress tumor growth; they may become polyploid by 
endomitosis ad endoreduplication. Most of them may eventually die. Adaptation IV. By about second week after exposure to 
genotoxins, a few of the tetraploid and polyploid cells with genetic or epigenetic alterations in the senescence pathway may 
undergo neosis to give rise to aneuploid Raju cells with transient stemness. These are the precursors of primary tumor growth 
with extended MLS. They mature into tumor cells. At the end of their limited MLS, they reach senescent phase and undergo S/
T-neosis and repeat the cycle of extended MLS, senescence, mitotic crisis and neosis several times, thus rejuvenating the supply 
of resistant (malignant) Raju cells in a highly non-synchronous fashion. (See the text for further details).Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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tion of the senescent phenotype is accompanied by sup-
pression of mitotic genes and overexpression of mitosis
inhibitor genes [Reviewed in [84,117]]. Accordingly, te
Poele et al., [118] have reported that in the archival breast
tumors from patients who had undergone chemotherapy,
when sectioned and stained for the senescent marker SA-
β-gal, 41% of the tumors stained positive. In untreated
controls only 10% of the tumors showed sporadic posi-
tive staining for SA-β-gal. Prof. E. Sikora, [Personal com-
munication] has obsrved that SA-β-gal positive cells can
undergo neosis, and tumor cells are apparently defective
in senescent checkpoint control(s), and chances are that
eventually some of these senescent cells might escape
senescence and give rise to resistant tumor growth via neo-
sis (see below). Therefore, induction of senescence as an
anti-cancer therapy should be approached with caution
for the following reasons:
1. Most of the genotoxins are carcinogens.
2. Tumor cells already have mutations in the senescent
checkpoint pathway. Therefore, the chances of some cells
escaping senescence are very high, especially in advanced
tumors.
3. Senescent cells secrete factors that can promote tumor
progression [81,119].
4. Senescent cells facilitate tumorigenesis in adjacent cells
[119].
5. Ageing senescent cells may accumulate additional
mutations due to oxidative damage and escape senescent
phase via neosis and may result in recurrence of resistant
tumor growth (See below).
6. Since most anti-cancer chemicals are carcinogenic, and
the tumor tissue is a mixture of normal and tumor cells,
chemotherapeutic drugs may facilitate tumorigenic trans-
formation of normal or preneoplastic cells [19].
Therefore, the approach of controlling cancer by inducing
senescence in vivo, although tempting, may in the long run
increase the chances of resistant tumor growth, or facili-
tate origin of new tumors. One has to better understand
the molecular events that regulate senescence and the
mode of escape from senescence in tumors, the longevity
and fate of senescent cells in vivo, before one can design
effective anti-cancer treatment strategies based on senes-
cence.
What is neosis?
Neosis is the newly defined mode of cell division that
occurs only in senescent, polyploid cells, and has not been
observed in normal diploid cells. Neosis is a parasexual,
somatic, reduction division displayed by a subset of
multinucleate and/or polyploid giant cells or MN/PG cells
formed during the spontaneous senescent phase of nor-
mal cells at the end of their MLS or genetic stress-induced
accelerated senescence phase in tumor cells. It is character-
ized by: (1) chromosome distribution to daughter cells
via nuclear budding in the presence of an intact nuclear
envelope, (2) followed by asymmetric cytokinesis, giving
rise to an indefinite number of small, aneuploid, mitoti-
cally active cells termed Raju cells (Raju meaning King in
Telugu language), after which the polyploid neosis
mother cell (NMC) dies. Raju cells display transient stem
cell-like properties, and mature into tumor cells with
extended MLS, finally arriving at a secondary/tertiary
senescent phase. Neosis is interspersed with the extended
MLS of Raju cells and their senescent phase and is
repeated several times during tumor growth in a progres-
sively non-synchronous fashion. Further, neosis is also
responsible for the outgrowth of resistant tumor cells after
exposure to genotoxins. Neosis appears to be a mode of
origin and continuous growth of different tumor types,
including hematological malignancies, carcinoma and
sarcomas. The significant role of neosis appears to be fine
tuning the damaged genome by epigenetic modulation in
order to escape death via stress-induced senescence [5,6].
Neosis-like events in the literature (Table 1)
Neosis-like events have been reported in the literature
sporadically for more than a century [120] under different
names [Reviewed in [6]]. Although to date, these events
were not generally correlated with any functional signifi-
cance, it is becoming clear that such a process is involved
in the escape of senescent cells into neoplastic cells
[Reviewed in [6]]. The earliest report that suggested a con-
nection between neosis-like events with escape from the
senescent primary cells was by Zitcer and Dunnabecke
[121]. These authors reported that human senescent
amniocytes bypassed senescence via nuclear budding fol-
lowed by cellularization. Zybina et al., [122,123] have
reported spontaneous polyploidization via endomitosis
and endoreduplication during the differentiation of
mammalian, extraembryonic placental trophoblast giant
cells in vivo. Polyploidization was followed by fragmenta-
tion of the nucleus via nuclear budding into small indi-
vidual aneuploid nuclei, resulting in synsytium-like post-
budding multinucleate giant cells. Near the end of preg-
nancy, small individual cells were formed by asymmetric
cytokinesis and cellularization. However, as in the case of
p53+/+ MEF/MGB cells [5], these individual cells disinte-
grated without any further mitotic division. Based on the
similarities between the steps involved in the maturation
of trophoblasts and the process of neosis (Table 2), it was
suggested [6] that gestational trophoblastic cancers
[124,125] originate via neosis due to compromise of
some tumor suppressor function at different stages of tro-Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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Table 1: Neosis-like events reported in different cell systems of different species. N* = normal cells, T* = transformed or tumor cells, 
M* = Mutant cells.
Species Cell type N* or T* 0r M* MN/PGs P- or S/T-neosis Trigger Conseuence Reference
1. Snail Primary cells N Yes P-neosis Senescence Established cell line Walen, 2004
2. Chicken Monocytes N Yes P-neosis Senescence Established cell line Solari et al., 1965
3. Marsupial Primary cells N Yes P-neosis Senescence Established cell line Walen, 2004
4. Mouse B16F10 melanoma cells Yes S/T-neosis (?) Methotrexate Resistant cell growth Baroja et al. 1998.
5. Mouse Embryonic stem cells M Yes P-neosis (?) Parp-less Teratocarcinoma Nozaki et al., 1999
6. Mouse C3H10T1/2 cells N Yes P-neosis X-ray Transformed foci Sundaram et al. 2004
7. Mouse C3H10T1/2 cells N Yes P-neosis Etoposide Transformed foci Sundaram et al. 2004
8. Mouse 1ET1-C3H cells T Yes S/T-neosis Spontaneous Progression Sundaram et al. 2004
9. Mouse 1ET1-C3H cells T Yes S/T-neosis X-ray Resistant cell growth Sundaram et al 2004
10. Mouse 1ET1-C3H cells T Yes S/T-neosis Etoposide Resistant cell growth Sundaram et al. 2004
11. Mouse P53-/- MEF/MGB N Yes P-neosis Senescence Spont. Transformation Sundaram et al. 2004
12. Mouse P53+/+ MEF/MGB N Yes P-neosis Senescence Non-viable Raju cells Sundaram et al. 2004
13. Mouse P53-/- MEF/129B N Yes P-neosis Senescence Spont. Transformation Sundaram et al. 2004
14. Mouse P53+/+ MEF/129B N Yes P-neosis Senescence Non-viable Raju cells Sundaram et al., 2004
15. Mouse L cells T Yes S/T-neosis(?) Arginine Resistant tumor growth Wheatley, Persnl communication
16. Armenian hamster AHL cells N Yes P-neosis X-ray Transformed foci Sundaram et al. 2004
17. Rat REF N Yes P-neosis X-ray Transformed foci Sundaram et al. 2004
18. Rat X-REF23 N Yes P-neosis X-ray Transformed foci Sundaram et al. 2004.
19. Rat Adenocarcinoma cells Yes S/T-neosis Cisplatin Resistant tumor growth Martin F, Persnl.communication
20. Mammals Trophoblasts N Yea P-neosis (?) Senescence Non-viable Raju-like cells Zybina et al., 1974, 1979
21. Human Amniocytes N Yes P-neosis Senescence Estabished cell line Zitcer and Dunnabecke, 1957
22. Human HT 1080 cells T Yes S/T-Neosis Chemical Resistant tumor cells Buikis et al., 1999
23. Human Breast epithelial cells N Yes P-neosis (?) Senescence Transformed cell line Romanov et al. q001.
24. Human Prostate cancer cell PC3 Yes S/t-Neosis Doxotaxol Resistant cell growth Marakovskiy et al 2002
25. Human Burkitt's lymphoma cells Yes S/T-neosis Radiation Resistant cell growth Ivanov et al., 2003.
26. Human Amnion cells N Yes P-neosis senescence Established cell line Walen, 2004
27. Human Amnion cells N Yes P-neosis SV40 Transformed cells Walen, 2004
28. Human Adenocarcinoma cells Yes S/T-neosis Spontaneous Tumor progression Sundaram et al. 2004
29. Human FSK cells N Yes P-neosis X-ray Non-viable Raju cells Sundaram et al. 2004
30. Human MRC-5 cells N Yes P-neosis X-ray Non-viable Raju cells Sundaram et al. 2004
31. Human HTB11 cells T Yes S/T-neosis Spontaneous Tumor progression Sundaram et al. 2004
32. Human HTB11 cells T Yes S/T-neosis X-ray Tumor progression Sundaram et al. 2004
33. Human HeLa cells T Yes S/T-neosis X-ray Tumor progression Sundaram et al. 2004
34. Human Colon carcinoma HT116 Yes S/T-neosis Doxorubicin Tumor progression Sikora E, Persnl communication
phoblast development. It is apparent that such a phenom-
enon is involved in the origin of tumor cells, due to
inadvertent expression of neotic gene(s) during DNA
damage-induced loss of p53 or related senescent check-
point genes.
Solari et al., [126] have reported continuous production
of small mononucleate Raju-like cells by nuclear budding
from multinucleate giant polyploid cells formed by fusion
of avian senescent peripheral blood mononuclear cells in
vitro, even in the presence of an inhibitor of mitosis. These
cells resembled Raju cells in their morphology and fused
again initiating secondary nuclear budding to yield the
next generation of Raju-like cells. Although the authors
did not discus the relationship of their observations to
senescence, immortalization or transformation of cells,
these events are very similar to the primary (P-neosis) and
secondary/tertiary or S/T-neosis reported by us [5,6].
Walen in a series of articles [127-129] has reported similar
nuclear budding giving rise to viable cells with continuous
division potential in different cell systems. Romanov et
al., [130] have reported the immortalization of senescent
human breast epithelial cells in vitro; although the exact
events of this process has not been described; they men-
tion a process of micronucleation, which could be the
process of nuclear budding related to neosis [5] or the
nuclear fragmentation that occurs during mitotic catastro-
phe [131].
While the above reports described the P-neosis-like events
in aging primary cells, recently S/T-neosis-like events have
been described in human cancer cell lines treated with
genotoxns. Upon exposure of human tumor derived
HT1080 cells to thiophosphomidium, cells reached a
rapid senescence state and produced 'macro cells' (poly-
ploid giant NMCs), which yielded small mononuclear
cells (Raju cells), by nuclear budding, a process termed
'sporosis' [132]. In a detailed study on Burkitt's lym-
phoma cells with mutant p53, Erenpreisa and her co-
workers [133-136] have described sequential events that
occur during radiation-induced neosis-like events that
resulted in the production of mitotically active Raju-likeCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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cells. Makaravskiy et al., [89] reported that exposure of
PC3 prostate cancer cells to docetaxel resulted in growth
arrest, multinucleation and giant cell formation, which
gave rise to docetaxel-resistant clones; this resistance was
associated with transient expression of a β-tubulin iso-
form and was independent of P-glycoprotein, bcl2 and
bcl-xl expression. The recent literature showing neosis-like
events are listed in Table 1. In every case, senescent MN/
PGs yield mononuclear Raju-like cells that display
extended MLS.
Neosis bypasses senescence
In 1998, using computerized video time-lapse micros-
copy, we started to study the cellular process involved in
transformed focus formation [5], which is considered to
be the in vitro equivalent of in vivo tumorigenicity [70-72].
This involved: (1) video documentation of the transfor-
mation process at the level of individual cells, (2) isola-
tion and cloning of the individual transformed foci
without being contaminated by surrounding non-trans-
formed cells, and (3) study the fate of these individual
neotic clones (Raju cells derived from a single neosis
mother cell or NMC) by serial cultivation under standard
culture conditions and under anchorage independent
conditions. These studies suggested that transformed
focus formation occurs via the novel process termed neo-
sis [5] and not via mitosis as previously thought.
Exposure of C3H10T1/2 cells to carcinogens induced
accelerated formation of large senescent MN/PG cells that
are supposed to be permanently arrested from undergoing
mitosis and eventually die via mitotic catastrophe
[19,81,137,138]. Around 14–21 days post-exposure to
carcinogens, a minor subset of these senescence-like MN/
PGs (hereafter termed the neosis mother cells or NMCs),
before they died, produced several small mononuclear
cells by karyokinesis via nuclear budding in the presence
of the intact nuclear membrane. Each nuclear bud was
immediately loaded with genomic DNA and surrounded
by a small fragment of the cytoplasm delimited by plasma
membrane by asymmetric cytokinesis. Each NMC pro-
duced about 10+/- 2 Raju cells. The latter were very small
(~6–8  µm in diameter), had very high N/C ratio and
immediately after birth, resumed symmetric mitotic divi-
sion, inherited aneuploidy and genomic instability; they
grew in soft agar, and displayed genotype and phenotype
different from the mother cell. Presumably, they have
reactivated telomerase expression [139-141] that resulted
in the extension of their mitotic life span (MLS). Thus
neosis and not mitosis is the mode of cell division result-
ing in tumorigenesis.
If neosis were the mode of transformation of normal cells
into neoplastic cells, the spontaneous transformation of
p53-/- mouse embryo fibroblasts should also involve
senescent phase followed by neosis. In fact this is what we
observed, when we studied the mode of spontaneous
transformation of p53-/- cells using a similar approach.
The primary cultures of p53-/- MEF/MGB cells entered
senescent phase at the end of its diploid mitotic life span
(about 6–7 passages), and almost all of these MN/PGs
underwent spontaneous neotic division, each giving rise
Table 2: Similarities between trophoblast maturation and tumor cell self-renewal
Properties Trophoblast Tumor cell
1. Subject to ageing and senescence Yes Yes
2. Polyploidization by endomitosis and 
endoreduplication
Yes Yes
3. Polyploid giant cell undergoes neosis Yes Yes
4. Activation of telomerase Yes Yes
5. Multiple neotic offspring Yes Yes
6. Degradation and migration through 
extracellular matrix
Yes Yes
7. Secretion of proteases degrades extracellular 
matrix
Yes Yes
8. Invasive properties Yes Yes
9. Proteolysis of thrombin receptor Yes Yes
10. Stimulation of invasive properties Yes Yes
11. Evasion of immune rejection Yes Yes
12. Activation of protooncogenes Yes Yes
13. Growth control by tumor suppressor genes Yes. Under normal circumstances No – Lost during neoplastic transformation
14. MLS of Raju cells or their equivalent Limited MLS and perish at the end of pregnancy Limited. Can extend MLS via repetitive S/T-
neosis.Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
Page 11 of 26
(page number not for citation purposes)
to 50 or more Raju cells, which by repetitive mitosis gave
rise to spontaneously transformed cell lines. All the NMCs
died within a month leaving the transformed cells in the
Petri plate. The isogenic control wild type p53+/+ MEF/
MGB cells underwent neosis yielding fewer number of
Raju cells, but these Raju cells died without yielding a
transformed cell line, probably due to the presence of
p53, which is detrimental to cells with genomic instability
[5,6,142] (see additional files 1, 2, 3, 4, 5, 6).
We also observed certain degree of plasticity in neosis,
where the nuclear budding during karyokinesis may
remain constant, but cytokinesis may follow immediately
to form Raju cells sequentially or be delayed to form post-
budding synsytium-like multinucleate cell, followed by
cytokinesis yielding several Raju cells simultaneously [6].
Raju cells transiently display stem cell properties
Raju cells are defined as the nascent daughter cells of
neotic division, before they undergo their first symmetric
mitosis. When the extended MLS of individual neotic
clones was studied by serial subculturing, around the 20th
passage they spontaneously underwent a senescent phase
and displayed mitotic crisis. Some of these MN/PGs spon-
taneously underwent secondary neosis, each NMC pro-
ducing ~10 +/- 2 secondary Raju cells, only to repeat the
cycle of EMLS followed by senescence, neosis, and pro-
duction of the next generation of Raju cells. [5].
We and others have reported neosis occurring in several
human and rodent tumor cell systems [5,6]. In tumor cell
cultures, neosis was repeated several times each neotic
division interspersed with extended, but limited, MLS of
the neotic offspring followed by a senescent phase. Thus,
during three years of continuous subculturing, human
metastatic neuroblastoma HTB11 cells underwent three
episodes of spontaneous senescence followed by S/T-neo-
sis and yielded new populations of mitotically active Raju
cells in a progressively non-synchronous fashion [5], (see
additional files 1, 2, 3, 4, 5, 6). The first and second epi-
sodes of mitotic crisis lasted for about 7 to 8 weeks (with
medium change twice a week) during which time the cells
remained in the senescent phase. The crisis period was
succeeded by neosis, giving rise to small, mononucleate
Raju cells with extended MLS. However, when HTB11
cells were subjected to carcinogen exposure, the senescent
phase lasted for only two weeks before the appearance of
Raju cells, reducing the duration of senescent phase and
mitotic crisis, indicating that genetic stress was high
enough to induce neosis within a shorter duration. This
implies that during spontaneous senescence and pro-
longed mitotic crisis (up to 7–8 weeks), the cells may
slowly be accumulating additional mutations (probably
due to oxidative stress) raising the level of genomic insta-
bility sufficient to induce spontaneous neosis.
We, therefore, hypothesize that self-renewal of cancer
growth is made feasible by the transient re-expression of
some stem cell properties in Raju cells. This, probably,
occurs after epigenetic modulation of the non-viable poly-
ploid genome of NMC prior to the neotic S phase or SN
phase. Unlike in the mitotic S phase or SM, where DNA is
replicated only once before each division, during the SN
phase, DNA is replicated several times and the newly syn-
thesized DNA is preferentially transported to the nuclear
bud, followed by asymmetric cytokinesis. Thus, the NMCs
display stem cell behavior in that the newly synthesized
genomic DNA is asymmetrically segregated to the daugh-
ter Raju cells [5,6]. The nascent Raju cell genome often
underwent mitotic division even before cellularization
while still within the cytoplasm of the NMC [6,133].
Raju cells are unique in that they transiently display cer-
tain stem cell-like properties such as extended, but limited
MLS, expression of telomerase, and potential to differen-
tiate. They entered symmetric mitotic division immedi-
ately after they became independent cells. The mitotic
derivatives of Raju cells grew larger in size and matured
into tumor cells in a couple of days, while undergoing
mitosis [5]. We interpret the increase in cell size during
the course of mitotic division as an embryonic cell prop-
erty that incorporates the G1 phase of the cell cycle
[6,143]. As they undergo symmetric mitotic proliferation,
they mature into tumor cells and probably undergo defec-
tive differentiation and gradually lose stem cell properties.
At the end of their extended, but limited MLS, the tumor
cells spontaneously entered a senescent phase. Since these
cells have already lost some senescent checkpoint path-
way gene(s) function, some of these senescent cells stand
a good chance of undergoing S/T-neosis, thus contribut-
ing to the continuity of tumor cell lineage. Thus, Raju cells
behave like committed stem cells immediately after birth
and slowly acquire somatic cell properties during the pro-
lipherative phase. Given in the box below are some of the
stem cell properties of Raju cells and the somatic cell
properties of their mitotic derivatives (Table 3).
Mitotic catastrophe and neosis are mutually exclusive with 
opposite effects
Chemotherapy and radiation therapy that target DNA as
well as the process of cell division have been used with
partial success as the main treatments of a variety of
human tumors [144]. In normal cells, cell cycle check-
points protect the cells from accumulating errors in the
genome by blocking cells at different points in the cell
cycle by enforcing the dependency of late events on the
completion of early events [145]. Exposure of cells to gen-
otoxins causes interruption of the progression of cell cycle
due to these different cell cycle checkpoint controls. The
individual cellular response to chemotherapeutic agents
will depend upon the nature of the agent used, the posi-Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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tion of the cell in the mitotic cell cycle, and the severity of
the cellular damage. Cells with acute lethal damage may
undergo immediate necrosis, or some of them will initiate
the process of programmed cell death or apoptosis, which
may lead to immediate cell suicide or delayed death by a
day or two. In rare occasions, the cells may complete sev-
eral mitotic divisions and the whole clone of cells might
die simultaneously at a later date. Almost all the surviving
cells will stop synthesizing DNA immediately. A major
fraction of the surviving cells recover from the shock after
several hours of quiescence and reenter cell cycle, proba-
bly after repair (or misrepair) of DNA damage. Most of
such cells do not show any alterations in their morphol-
ogy or growth behavior at least immediately after recovery
[Fig. 1].
Of all the different checkpoint controls the most impor-
tant one is the mitotic checkpoint or the spindle check-
point, which is considered the primary defense against
aneuploidy and ensures accurate chromosome segrega-
tion in order to produce genetically identical daughter
cells [90,146]. During karyokinesis in mitosis and meio-
sis, the nuclear envelope is dismantled at which time the
spindle checkpoint is activated [146,147]. Often the
senescent cells form nuclear envelopes around fragments
of the genome, a process termed micronucleation
[131,148,149]. Thus, unable to maintain G2 arrest, they
enter mitosis and after being arrested for several hours at
metaphase, they eventually die without successfully com-
pleting mitosis. This process is known as mitotic catastro-
phe or mitotic death [150,151,154,155].
Since most cancer cells are deficient in the tumor suppres-
sor function of the p53/pRB/p16INK4a signal transduc-
tion pathway, the G1, and G2 checkpoint functions are
lost. After uncoupling apoptosis from G1 and S, tumor
cells with mutant p53 arrive at G2/M interphase, at which
time decisions regarding cell survival and death may be
initiated. Cells that did not repair the damage to DNA
arrive at G2 with point mutations and double strand
breaks. Some of the double strand breaks are repaired by
homologous recombination and non-homologous end
rejoining during the G2 arrest [152,153]. Most of the sur-
viving cells with unrepaired chromosomal lesions activate
the senescent program via the DNA damage response.
Senescent cells are characterized by SA-β-gal expression,
SAHF, and are usually very large due to endomitosis and
endoreduplication and are generally unable to divide
again even in the presence of growth factors. Further, the
senescent cells downregulate mitotic genes and upregu-
late anti-mitotic genes [19,81,84]. Under these circum-
stances, the senescent cancer cells will face inevitable
death, unless they adapt and evade cell death, by eliminat-
ing the mitotically non-viable genome, and multiply by
producing mitotically viable genome in order to be able to
maintain the continuity of tumor cell lineage. All these
conditions are fulfilled by neosis [5]. In this connection,
it is interesting to note that senescent SA-β-gal positive
Table 3: Properties of Raju cells and their mitotic derivatives:
Transient stem cell properties of Raju cells:
1. Short cell cycle duration of nascent Raju cells (before they undergo first mitosis) – an indication of lack of G1 phase? [5, 6].
2. Reactivation of telomerase conferring extended mitotic life span [139-141].
3. Is it possible to expand Raju cell population without differentiation under proper culture conditions such as EGF or FGF2 [43, 144-148].
4. Increase in cell size accompanied by increase in cell cycle duration-introduction of G1 phase in the cell cycle [Rajaraman, unpublished; 143].
5. Resistance to genotoxins – Expression of multidrug resistance genes? [192, 193].
6. Are they transiently expressing tissue stem cell specific surface markers? (e.g., CD34+ for hematopoietic cells [8]; CD133+ for brain cells [12, 
13], CD44+, CD33-, LowLin- for breast cells [9-11]; CD20+ for skin cells [40]; CD44+,α 2β 1hi/CD133+ for prostate cancer cells [41].
7. Are they transiently expressing stem cell specific growth genes? (E.g. Nanog, Oct-4, Wnt, Bmi1 etc.) [188-191]
8. Potential to differentiate, although aberrantly.
Somatic cell properties of mitotic derivatives of Raju cells:
1. Resumption of symmetric mitotic division.
2. Increase in cell size – Introduction of G1 phase in the cell cycle? [143].
3. Progressive, but, aberrant differentiation.
4. Loss of tissue specific stem cell surface markers due to differentiation during extended mitotic proliferation?
5. Loss of expression of stem cell specific self-renewal genes?
6. Loss of expression of multidrug resistance genes?
7. They are subject to aging and associated senescence brought about by telomere attrition.
8. Therefore, they have limited division potential.
9. Telomere attrition, chromosome breakage-fusion-bridge cycle or genetic stress will result in senescent phase with MN/PG formation, mitotic 
crisis, and mitotic catastrophe.
10. Absence of senescent check points constitutes a built-in mechanism for accumulation of additional mutations via breakage-fusion-bridge 
cycle, setting in motion the next cycle of S/T-neosis [66, 67].Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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cells formed after exposure of human colon carcinoma
HT116 cells to doxorubicin underwent nuclear budding
and formed Raju cells via neosis [Prof. E. Sikora, personal
communication].
We postulated that during such critical time of mitotic cri-
sis, the cells may revert back to neosis, which may be an
evolutionary throw back just to tide over the crisis [5].
Interestingly, this mode of cell division resembles the
asexual reproduction found in parasitic protozoans and
protista and has been reported to be an evolutionary
phase in sexual reproduction by meiosis in higher organ-
isms [153]. However, it has been demonstrated that such
a primitive mode of cell division is still being activated
during the maturation of extraembryonic tropholast cells
during mammalian pregnancy. Thus, it appears that the
gene(s) that execute neosis are still functional in the mam-
malian genome, which are supposed to be active only dur-
ing the trophoblast maturation in the extra embryonic
tissue during pregnancy [122,123], and are inadvertently
expressed in the absence of certain tumor suppressor
genes (p53?) due to DNA damage.
When tumor cells are exposed to conventional chemo-
therapy or radiation therapy, most of the accelerated
senescent cells may eventually die, but some do escape by
adapting to the adverse conditions by undergoing poly-
ploidization, and karyokinesis via nuclear budding
[5,133]. Since mitotic checkpoint or spindle checkpoint is
activated only after the dismantling of the nuclear enve-
lope [146], polyploidization followed by nuclear budding
with an intact nuclear envelope is bound to protect the
NMC from cell death due to mitotic checkpoint. There-
fore, some of these polyploid cells successfully undergo
reduction division or de-polyploidization yielding near
diploid daughter Raju cells with transient stem cell prop-
erties [5,6].
When spindle checkpoint is defective, a minor fraction of
senescent cells escape mitotic catastrophe and become
tetraploid due to mitotic slippage or cytokinesis failure
[154,155]. Such cells have been shown to undergo
multipolar mitosis giving rise to aneuploid cells [154].
However, it is not sure if these aneuploid cells will survive
long enough to contribute to the clonal selection in tumor
tissue [156]. We have shown that a subpopulation of
tetraploid cells can undergo neosis by nuclear budding to
give rise to several daughter cells before they die [5]. Since
the nuclear envelope is not dismantled during neosis,
spindle checkpoint is probably not activated and this
might favor successful completion of neosis, often acci-
dentally yielding aneuploid neotic offspring, which may
survive and proliferate due to loss of genomic stability.
During mitotic catastrophe, nuclear envelope is disman-
tled and spindle checkpoint is activated, leading to
mitotic catastrophe via micronucleation and death
[20,84,148-150]. Thus, mitotic catastrophe and neosis are
mutually exclusive phenomena displayed by tumor cells
with opposite effects. While the former eliminates the
tumor cells with a defective genome, the latter helps adapt
them to genomic instability-induced accumulation of
genetic and epigenetic alterations by reducing the GI load
in the neotic offspring via epigenetic modulation and thus
contributing to the continuity of tumor cell lineage.
Neosis and epigenetics in tumor progression
Epigenetic modulation is probably the way the genome
alters its behavior in response to the environment [157].
"The genome functions like a highly sensitive organ of the
cell that monitors its own activities and corrects common
errors, senses unusual and unexpected events, and
responds to them, often by restructuring itself" [158]. This
statement probably accurately fits the behavior of cancer
cells. Recent studies have revealed that genetic mutations
alone do not lead to cancer and that epigenetics plays a
major role in the origin and progression of tumors. Epige-
netic alterations – non-DNA sequence-based heritable
alterations – have been shown to initiate genomic insta-
bility, even before gene mutations enter into the process
[159-162]. Epigenetic mutations fall into two main cate-
gories: (1) Altered DNA methylation of CpG dinucle-
otides, both losses or hypomethylation (results in gene
activation) and gains or hypermethylation (results in
silencing the gene) and (2) altered patterns of histone
modifications such as acetylation or deacetylation of
lysine residues, [160-166].
Epigenetic modulation occurs during all stages of tumor
growth from the initiation at the progenitor cells through
tumor formation and progression [162,163]. During the
initiation stages, epigenetic modifications mimic the
effect of genetic damage by altering the expression of
tumor suppressor genes, thus compromising the tumor
suppressor function of the senescence program; for exam-
ple, silencing of tumor suppressor genes by promoter
DNA hypermethylation and chromatin hypoacetylation,
which may affect the expression of diverse genes including
p53, RB1, p16INK4A, Von Hippel-Landau tumor suppres-
sor (VHL) and MutL protein homologue 1 (MLH1)
[109,162,163,168-170]. Global hypomethylation of
chromatin and loss of imprinting lead to chromosomal
instability and increased tumor incidence both in vitro and
in vivo [165-167]; epigenetic activation of R-ras is respon-
sible for gastric cancer [168] and cyclinD2 and mapsin
activation in pancreatic cancer [169,170].
Tumor cells constitutively express some meiotic genes
called Cancer/Testes (CT) antigens [171-174]. Immedi-
ately after exposure to radiation, some of these meiotic
genes were translationally upregulated in NamalwaCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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Burkitt's lymphoma cells with p53 mutant gene [175]. It
has been recently demonstrated that exposure of tumor
cells to genotoxins results in the translational upregula-
tion of cMOS gene [175], which is involved in switching
cells from mitosis to meiosis II and forcing the cell to
undergo reduction division [172]. Constitutively
expressed in low levels in untreated tumor cells, expres-
sion of meiotic cohesion gene REC8 was also enhanced
after irradiation of p53 mutated Namalwa Burkitt's lym-
phoma cells, along with other meiosis-specific genes
DMC1, STAG3, SYCP1 and SYCP3. Expression of these
genes reached a peak level during the mitotic arrest phase
and was proportional to the endopolyploid cells [175].
When such defective cells reach senescent phase and
undergo neosis, these polyploid NMCs give rise to near-
diploid or aneuploid Raju cells; this indicates that neosis
must comprise properties of meiosis, mitosis and neosis
specific events. During the extended MLS, Raju cells differ-
entiate into tumor cells, while also accumulating addi-
tional mutational and epimutational alterations. This will
increase the GI load, and cells will arrive at the next senes-
cent phase due to incomplete differentiation displaying
mitotic crisis. The onset of senescence is accompanied by
several changes in the gene expression profile of the cells:
(1) downregulation of mitotic genes; (2) upregulation of
anti-mitotic genes [19,84]. During neosis the following
changes in the gene-expression profile must occur: (1)
reexpression of the 'immortalizing enzyme' telomerase is
obligatory for the extension of mitotic life span, but not
sufficient for neoplastic transformation [139-
141,176,177]; (2) ectopic expression of meiotic genes col-
lectively called cancer/testes (CT) antigens in tumor cells,
which are thought to play a role in transformation [171-
178], (3) in addition to ectopic expression of stem cell
self-renewal genes including microRNAs, notch, oct4, and
Bmi1 [77,179-184] and (4) multidrug resistance genes
[185,186]. Therefore, the most significant event during
neosis appears to be the alteration in gene expression pro-
file, which is likely to be brought about by epigenetic
modulation. This will in effect reduce the GI load, making
it possible to produce mitotically viable genomes of Raju
cells from the non-viable polyploid genome. Our data
and those of others [5,6,127-129,152,153,175,187] sug-
gest that the genome of such polyploid cells, although not
mitotically viable, may undergo epigenetic modulation in
order to reduce the degree of GI load to yield mitotically
active daughter Raju cells with EMLS and thus contribute
to the continuity of tumor cell lineage in a non-synchro-
nous fashion, while the mitotically non-viable polyploid
genome is eliminated by the post-neotic death of NMC.
Thus, the genes for neosis which are silent in the genome,
and should be active only during the maturation of the
extraembryonic trophoblast cells during pregnancy
[122,123], are reexpressed in tumor cells in the absence of
p53 or related tumor suppressor genes due to DNA dam-
age.
Neosis is repeated several times during the growth of
tumors. This implies that global epigenetic modulation
occurs throughout the life of the tumors, repetitively at
least during each neosis, since continuous proliferation
will lead to accumulation of gene mutations and epimu-
tations, which may be often detrimental to the cell. There-
fore, we propose that during neosis the cell with defective
senescence checkpoint control(s) tend to undergo endore-
plication/multinucleation and after restructuring the
genome followed by multiple rounds of neotic S phase
(SN phase), produces daughter Raju cells with EMLS via
nuclear budding and asymmetric cytokinesis. This
decreases the GI load in the Raju cells, while the non-via-
ble polyploid genome of the NMC is discarded during its
post-neotic demise. In the absence of tumor suppressor
gene(s), the genome appears to be highly plastic (and tol-
erant to DNA damage) and responds to the damage and
never activates the mitotic checkpoint by keeping the
nuclear envelope intact and tides over the crisis by pro-
ducing several Raju cells with stem cell properties and
helps the continuous growth of tumor.
5.6. Neosis as the source of aneuploidy
The question of the source and mechanism of the origin
of aneuploidy is still being debated [188]. More than a
century ago, Hanesmann [189] and Boveri [120], sug-
gested that aneuploidy is the result of non-disjunction
during bipolar division or multipolor mitosis, respec-
tively. The rare occurrence of pluripolar spindles repre-
sented Boveri's paradigm for a type of abnormal mitosis
that can produce a variety of random chromosomal com-
binations. Unbalanced bipolar divisions or pluripolar
mitoses will fail to distribute the chromosomal material
to the daughter cells correctly. Therefore, both of these
mechanisms can potentially give rise to tumor progenitors
[120,189,190]. Accordingly, a parasexual cycle of poly-
ploidization and segregation of chromosomes has been
reported to occur in human fibroblasts, which has been
assumed to involve multipolar spindle formation and
chromosome non-disjunction [191,192]. However, it
should be pointed out that the observations of both
Hanesmann [189] and Boveri [120] were largely made in
tumor cell populations, which led them to arrive at this
conclusion. Since tumor cells have already lost genomic
stability, they could tolerate errors in chromosomal distri-
bution and continue dividing in order to survive [193].
Therefore, this does not address the question of origin of
aneuploidy. We propose neosis as the third and most
likely mode of arriving at aneuploidy for the following
reasons:Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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(1) It has been shown recently that structural and numer-
ical chromosome alterations in colon cancer develop
through telomere-mediated anaphase bridges and not
through mitotic multipolarity. In fact, multipolarity
results in uneven chromosome distribution to daughter
cells that gives rise to gross genomic changes such as nul-
lisomies and non-viable daughter cells, and therefore,
rarely contributed to clonal evolution tumor cells [194].
(2) It now seems that all human aneuploidies (cells that
have chromosome number other than 46) in normal dip-
loid human cell systems that occur during development
result in embryonic lethality, except certain combinations
of sex chromosomes and hyperdiploid, trisomies 13, 18
and 21, which yield severe birth defects in humans
[195,196].
(3) Further, it has been recently shown that chromosome
non-disjunction in primary human cells yields tetraploid
cells rather than aneuploid cells due to failure of cytokine-
sis. This demonstrates that tetraploid cells do not directly
give rise of aneuploidy. Therefore, there must be an inter-
mediate step between tetraploid cells and the origin of
aneuploid progeny of tumor cells [197].
(4) We observed primary neosis that gave rise to trans-
formed cells in a binucleate giant cell with a chromosome
bridge [5]. The fact that this NMC is binucleate with an
isthmus, indicates that this cell has undergone one unsuc-
cessful mitotic division attended by cytokinesis failure
and has, therefore, an at least tetraploid genome.
(5) Thus, neosis appears to be the intermediate step
between tetraploid cells and the origin of aneuploid
tumor cells. It has the potential to give rise to aneuploid
or near diploid stem cell-like Raju cells via polyploidiza-
tion followed by karyokinesis via nuclear budding with-
out activating mitotic checkpoint control by keeping the
nuclear envelope intact.
(6) Accordingly, p53-/- MN/PG cells spontaneously gave
rise to transformed cells via neosis [5] and in p53 null
mouse cells cytokinesis failure-generated tetraploid cells
promote tumorigenesis in vivo [198].
(7) These cells have extended MLS in the absence of senes-
cent checkpoint controls (e.g. P53-/- cells); but they perish
in the presence of proper checkpoint controls (eg., p53+/
+ cells). Thus, p53+/+ MN/PG mouse cells did not yield
viable Raju cells [5,6] and the p53+/+ tetraploid cells did
not produce tumors in vivo [198].
(8) In support of this, it is also known that in several
human and rodent tumor systems, tetraploidy is the inter-
mediate stage before the genesis of neoplastic growth
[155,156,199-203].
Therefore, we propose that senescent cells with tetraploid
or higher ploidy genomes have the potential to under go
neosis, creating conditions for automatic onset of aneu-
ploidy to drive malignancy [67], if all the conditions for
survival of the genome are met with in the resultant Raju
cells.
Polyploidy can result either due to endomitosis and
endoreduplication, or by cell fusion. It has been shown
that Mad2- or BubR1-depleted cells (the genes involved in
spindle checkpoint control) that do not complete cytoki-
nesis remain viable through continued cycles of DNA rep-
lication up to at least 32 N [146,205]. In murine
melanoma cultures exposed to methotrexate, emergence
of resistant clones is preceded by an increase in polyploid
cells with DNA content >8c and even >16c, concomitant
with a decrease in tetraploid cells and is accompanied by
loss of expression of mtotic proliferation markers (PCNA
and CDK1) [206]. Even higher ploidy can be attained in
certain cell systems [121-124,133]. Polyploidization, in
addition to protecting cells from death confers evolvabil-
ity by producing cells with non-lethal variations in the
genome, upon which the process of natual selection may
act [5,207,208]. In addition, since spindle checkpoint
control is activated after the dissolution of the nuclear
envelope [146], neosis, by performing karyokinesis via
nuclear budding without the dissolution of the nuclear
envelope, appears to be an adaptation by polyploid cells
to escape from spindle checkpoint control-induced
mitotic catastrophe. It is known that p53 null cells even-
tually develop polyploidy [5,156,197,198] attended by
multiple centrosomes.
Often the presence of multiple centrosomes can avoid for-
mation of multiple spindle poles by fusion of centro-
somes resulting in a complex form of bipolar spindle
[154,209]. However, it remains to be elucidated as to how
the process of karyokinesis is effected in the presence of
nuclear envelope. The question arises if the complex of
multiple centrosomes acts like the spindle pole body of
budding yeast by physically associating itself with the
nuclear envelope and relocating itself back in the cyto-
plasm in Raju cells [129] so that they can resume symmet-
ric mitosis.
Approximately one week after exposure to genotoxin, the
chromatin in the endopolyploid giant cells reorganizes
into a bouquet-like structure resembling meiotic
prophase [132]. By about post-exposure day 14–21, some
of these cells spontaneously undergo neosis and produce
aneuploid Raju cells, the progenitors of tumor cells
[5,127]. The latter undergo symmetric mitotic divisionCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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and survive due to loss of checkpoint control(s) and gain
of genomic instability. The role of meiotic genes in favor-
ing reduction in the number of chromosomes during neo-
sis is strongly suspected [175]. Similarly, multiple cycles
of DNA replication in the NMC can be made possible by
some meiotic gene(s) that are ectopically expressed in
tumor cells [171-173][174]. Therefore, we suggest that, in
addition to the global epigenetic modulation of the
genome discussed above, neosis, rather than multipolar
mitosis, is involved in the origin of aneuploid tumor cells.
However, we envisage that once the genesis of tumor cells
via neosis is achieved, since these cells have gained
genomic instability, further propagation of aneuploidy
and the associated chromosomal aberrations including
gene duplications, translocations etc will be facilitated by
the various mechanisms including centrosome amplifica-
tion, mitotic spindle abnormalities, defective attachment
of chromatids to kinetchore, telomere dysfunction-
induced breakage-fusion-bridge cycle, defective cytokine-
sis, mitotic checkpoint defects, among other things [188].
Thus, once the process of aneuploidy is initiated by neo-
sis, progressive increase in aneuploidy might play an
active role in the on-set of aggressive malignant property
in solid tumors, whose survival and proliferation may be
favored by loss of genomic stability [66].
The basis for the number of Raju cells produced by each
NMC is not known. For example, in p53 MEF/MGB cells
we observed that there were multiple giant nuclei present,
and often more than one nucleus can produce nuclear
buds and yield Raju cells. Number of Raju cells/NMC was
around 10+/- 2 in C3H10T1 1/2 cells, ~4 or 5 in HeLa
cells, and ~50 or more in p53-/-MGB/MEF cells, but 1 or
2 in p53-/-MEF/129B cells. While it is tempting to postu-
late that the number of Raju cells/NMC may depend upon
the ploidy of the NMC, this remains to be tested. It is very
likely in addition to ploidy, the cellular genetic back-
ground may be a determining factor in the number of
Raju cells/NMC [5].
Additionally, it is known that cancer cells are living precar-
iously at the edge of life [23]. While these cells have shut
off spindle checkpoint and escaped mitotic catastrophe,
and are on the way to escaping senescence, anything can
go wrong in the process of neosis and cells may die at any
stage of neosis, a process which we have termed neotic
catastrophe. Thus, even at the last phase of neosis the
NMC may die without yielding daughter cells, even after
they have been successfully formed, for the simple reason
that they cannot get out of the mother cells and become
independent cells [5].
Limits of extended Mitotic Life Span (MLS) and tumor 
progression
Neotic clones isolated from C3H10T1/2 cells exposed to
etoposide displayed extended MLS, probably due to reex-
pression of telomerase [5,6,139-141]. Contrary to the
belief that transformed cells are 'immortal,' we observed
that at about the 20th passage, the neotic clones entered
the next cycle of senescence and underwent secondary
neosis yielding the next batch of Raju cells, which contin-
ued to multiply [5,6]. Tumor cells undergo spontaneous
senescence in vivo and display the senescence marker SA-
β-gal sporadically [118] in a non-synchronous fashion.
This implies that transformation does not confer immor-
tality. Instead, this simply results in extension of the MLS
of neotic offspring, which would not be feasible if it were
not for the rejuvenation process of neosis. In addition,
this observation suggests that the 'stemness' of Raju cells
was transient and this property is lost during the prolifer-
ative phase, probably due to defective differentiation,
which leads to the hierarchic nature of the tumor cell pop-
ulation. This important aspect of cancer cell mortality
would not have been revealed if we did not study the
behavior of individual neotic clones [5]. Under normal
circumstances, the progenies of different NMCs will be
growing either in vitro or in vivo, masking the repetitive
renewal or rejuvenation of MLS via neosis, especially since
this is occurring in a non-synchronized fashion.
Similarly, the human renal adenocarcinoma ACHN cells
displayed rare MN/PG cells that initiated S/T-neosis;
while in human metastatic neuroblastoma HTB11 cells,
after continuous culture in vitro a high frequency of cells
were observed to enter S/T-neosis [5]. Although we do not
have any experimental data on the length of the extended
MLS in these systems, the fact that these cells also display
senescent MN/PGs that act as NMCs implies that cancer
cells are not immortal, and that they also undergo sponta-
neous senescence due to differentiation and ageing [5] or
accelerated senescence after exposure to anti-cancer agents
[210]. However, the senescent cells may escape death
since these are tumor cells with defective senescent check
point control(s) and their growth is rejuvenated incon-
spicuously, since neosis is not synchronized.
Although there is limited knowledge about the genetics of
life span and senescence, there are probably many genes
involved in regulating these processes [211-213]. As the
continuity of cancer cell lineage is facilitated by repetitive
cycles of senescence followed by S/T-neosis and EMLS of
tumor cells through cancer progression, there is increasing
degree of non-synchrony in the onset of senescence. The
senescence program is not intact in tumor cells. In addi-
tion, during the proliferative phase the tumor cells are
known to accumulate additional random mutations
increasing the degree of genomic instability load (GICancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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load) [5,6,214]. It is likely that additional mutations or
epimutations in the cancer cell genome would include the
senescence genes, pro-apoptotic genes and genes that
favor neosis. While such changes in the neosis-specific
genes might have a negative selection effect, mutations or
epigenetic changes in the senescent, pro-apopotic and
longevity genes might have the opposite effect, contribut-
ing to the length of the extended MLS of tumor cells. How-
ever, one would expect an increase in the frequency of S/
T-neosis due to the genetic stress caused by high GI load
and accumulation of further mutational events in the
genome. Additionally, tumor cells undergo defective dif-
ferentiation, and this would also contribute to mitotic cri-
sis along with the exhaustion of EMLS, leading to the next
senescent phase. Thus, in malignant populations of cancer
cells, one can expect to see a higher frequency of such cells
may escape senescence via S/T-neosis. This is what we
observed in the case of metastasizing neuroblastoma
HTB11 cells [[5],; Rajaraman, unpublished]. It is tempting
to suggest that in malignant tumor cell population, the
NMCs may not display senescent markers such as SA-β-
gal. The course of events that overcomes cellular senes-
cence in human cancer pathology supports the above con-
clusion, even though the study did not involve neosis. For
example, in the case of transitional cell carcinoma (TCC)
that represents superficial bladder tumors and invasive
bladder cancers, the superficial bladder tumor cells
expressed p16 after limited in vitro passage and senesced
as did the normal human uroepithelial cells, while all the
muscle invasive TCCs contained altered p16 or pRB and
bypassed senescence [215]. These data suggest that early
tumors display senescence phase, while malignant tumors
might have lost the efficiency of senescence barrier proba-
bly due to additional mutational events in genes that are
involved in effecting the senescence program.
. When C3H10T2/3 mouse cells were exposed to 20 µM
etoposide, the resultant neosis yielded Raju cell deriva-
tives that were 25 times more resistant to etoposide; and
they survived and underwent S/T-neosis even after expo-
sure to 500 µM etoposide. The parent cell line died within
a few days after exposure to 500 µM etoposide [5]. Prof.
Martin reports that when rat colon adenocarcinoma cells
were exposed to cisplatin, the resultant neotic progeny
displayed resistance to genotoxins [Personal communica-
tion]. Makarovskiy et al. [89] have observed emergence of
docetoxyl resistant prostate cancer PC3 cells after poly-
ploidization. Erenpreisa and her coworkers have reported
that when Burkitt's lymphoma cells were irradiated, the
resultant neotic progenies were resistant to radiation
[216]. Thus, neosis appears to be the primary source of
epigenetic changes that fine tunes the damaged, non-via-
ble polyploid genome to yield mitotically viable genome
after global epigenetic modulation, and therefore, is the
mechanism of recurrent growth of resistant tumor cells
after chemotherapy or radiation therapy. It is proposed
that when tumor cells are subject to adverse conditions in
vivo or in vitro, cells undergo a rapid senescence phase and
some of them may escape cell death by undergoing neosis
and give rise to resistant tumor growth.
Up to ~10% of the cells in a given tumor tissue may be
senescent cells (MN/PGs or potential NMCs). Senescent
cells expressing SA-β-gal may undergo neosis [Dr. E.
Sikora, personal communication]. At any given time, few
of these potential NMCs in a tumor tissue will undergo S/
T-neosis, thus replenishing the population of Raju cells,
which will be subject to clonal selection. The individual
neotic colonies are different from each other both pheno-
typically and genotypically [5]. Thus repetitive, non-syn-
chronous neosis in tumor tissues constantly introduces
heterogeneous populations of Raju cell derivatives, which
will be subject to natural selection. Therefore, neosis is
involved in maintaining the continuity of tumor cell line-
age at times of mitotic crisis by producing resistant clones.
This will result in the selection of progressively malignant
cells, leading to tumor progression.
Significance of neosis as a self-renewal mechanism
An unequivocal knowledge of the source of cancer cells
and their mechanism of self-renewal have a special signif-
icance in developing effective anti-cancer therapeutic pro-
tocols, if one wants to kill cancer cells specifically without
affecting the normal stem cells and somatic mitotic cells.
Although the concept of cancer stem cell is very appealing
(more than 31,000 articles have been published in sup-
port of this concept), it is still controversial [6,42,44]. In
the absence of direct and compelling evidence for the
asymmetric division potential of CSCs, and the recent
emergence of evidence for the role of telomere attrition
causing senescence in (adult) stem cells [52,53] and
escape from senescence in the absence of senescence
checkpoint control(s) [63], it is difficult to consider the
concept of immortal CSCs as the source of cancer self-
renewal.
On the other hand the use of transformed focus formation
assay has demonstrated that neosis is not only the mode
of origin of tumor cells with genomic instability, but also
is an efficient mechanism of self-renewal that helps main-
tain the continuity of tumor cell lineage and is the mode
of escape from senescence and mitotic catastrophe [[5,6]
Prof. E Sikora, personal communication]. It is also
involved in the origin of drug-resistant tumor growth
[[5,6,89,132] Prof. F. Martin, personal communication].
Additionally, as discussed above, neosis appears to be the
source of aneuploidy in tumor cells.
It is noteworthy that the NMCs resemble stem cells in that
they undergo asymmetric division by segregating theCancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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newly synthesized viable genome to the daughter Raju
cells, while retaining the non-viable defective polyploid
genome, which is eliminated after the production of
daughter Raju cells. The latter also display some degree of
"stemness" in that they have gained extended MLS, indi-
cating reactivation of telomerase; they have the potential
to undergo differentiation, albeit aberrantly, and act as
tumor initiating cells, contributing to the continuity of
tumor cell lineage. Newer populations of mortal, but
resistant (malignant) Raju cells with survival advantage
due to transient expression of stem cell properties, which
are repetitively produced via non-synchronous S/T-neosis
due to selection pressure are operative in different tumor
systems studied so far. This process appears to be a potent
mode of self-renewal in tumor tissues. Taken together,
these observations indicate that ESCs, ASCs and the tran-
sit amplifying cells, like the non-stem somatic cells
[50,52,53,63,217] can also undergo senescent phase fol-
lowed by extension of MLS, via neosis. This supports the
alternative inference of the in vivo carcinogenic suscepti-
bility data (see above) that the ASCs and their asymmetric
mitotic progeny of transit amplifying cells, and not just
the ASCs alone, are susceptible to carcinogen-induced
mutational events (see above). In fact, the Raju cells with
stem cell-like properties behave like committed stem cells
or progenitor cells that lose their 'stemness' during their
transit amplification and differentiation phase.
7. Cancers as a single disease of uncontrolled growth via 
neosis
Classically, cancer is considered a heterogeneous group of
disorders with unlimited mitotic potential (immortal)
and with markedly different biological properties, which
are the result of clonal selection of mutant tumor suppres-
sor genes and oncogenes. [218-222][223]. Thus, almost
200 different types of cancers, as many as the number of
different types of cells in the human body, have been rec-
ognized, each with its own characteristic signal transduc-
tion pathways and with unique mutations in these
differentiation pathways. Since each type of differentiated
cell would reach its maturity via different signaling path-
ways, each type of cancer might have different molecular
abnormalities that will be responsible for the uncon-
trolled growth of cancer [221]. This will be further com-
plicated by the number of potential proto-oncogenes or
tumor suppressor genes in the signal transduction path-
ways that can mutate or epimutate to cause cancerous
growth. Further, the same gene may not carry an identical
mutation even within a group of patients with one type of
cancer [220]. This makes it very difficult for the modern
approach of developing targeted therapy to treat cancers
in a highly specific fashion for the individual cancer types
and since the anticancer therapy is directed against mitotic
tumor cells, in due course tumors become resistant to
these drugs [224][225], probably, due to S/T-neosis-medi-
ated emergence of resistant cells.
However, recent data, including ours suggest that tumor
cell heterogeneity is due in part to epigenetic variation in
the progenitor cells, and the epigenetic plasticity in addi-
tion to genetic variation is responsible to drive tumor pro-
gression [160,161]. This concept has added significance to
ageing since even maternal twins display epigenetic differ-
ences as a function of their age and the environment they
were brought up [164], This has resulted in great interest
in the role of epigenetic mechanisms in the origin and
progression of tumors [160-162].
Preliminary data indicate that neosis may be the common
denominator for both solid tumors and hematological
malignancies [5,6]. Up to 10% of the tumor cells are poly-
ploid giant cells. Since these are the potential candidates
for S/T-neosis to occur, effective elimination of these dis-
tinct populations of cells will reduce the chances of fur-
ther progression of tumors. If one can successfully identify
a common molecular step specific for neosis (see below
for examples) among different cancer types, one can con-
ceptualize cancer as a single disease caused by genesis and
regenesis of Raju cells via neosis from the point of view of
therapeutic molecular targeting. The common features of
neosis in hematological malignancies, and solid tumors
including carcinomas and sarcomas, may include DNA
damage response-induced repair or misrepair, DNA
polymerase(s) involved DNA repair and in polyploidiza-
tion, epigenetic genome and chromatin modulation, acti-
vation of telomerase, DNA polymerase(s) involved in
repetitive neotic DNA synthesis, karyokinesis via nuclear
budding and asymmetric cytokinesis. This, hopefully,
reduces the number of signal transduction pathways that
can be altered during carcinogenesis in order to be able to
interfere in the process of carcinogenesis. Thus design and
development of an ideal anti-neotic agent or neociside to
block the progression of multiple types of cancers may be
simpler than the steps involved in identifying and devel-
oping molecular targets dependant on mitotic genes for
individual cancer types or individual patients. Addition-
ally, since senescent cells and therefore, neosis may not
occur in normal somatic cells active in mitosis, the collat-
eral damage to normal mitotic cells is bound to be highly
reduced.
Neosis paradigm of multistep carcinogenesis
Several theories of carcinogenesis have been proposed so
far including: (1) the theory of step-wise accumulation of
gain of function mutations in oncogenes and loss of func-
tion mutations in tumor suppressor genes [179]; loss of
checkpoint control leading to genomic instability [2]; (3)
aneuploidy-induced genomic instability [66]; (4) senes-
cent checkpoint and telomere attrition [63,128,129]; (5)Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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mutations in the apoptosis genes [126]; and (6) a combi-
nation of epigenetic and genetic alterations leading to
genomic instability and tumorigenesis [160-164], among
others.
The neosis paradigm of multistep carcinogenesis pro-
posed by us encompasses all of the above phenomena,
since the cancer cells seem to exploit these various phe-
nomena during different stages of their evolution into
malignancy. However, the major difference is that neosis
and not mitosis is involved in the origin of tumors while
tumor progression involves repetitive S/T-neosis inter-
spersed with an extended, but limited, MLS and senes-
cence between two neotic events [5,6]. Additionally, the
common belief is that only stem cells are the progenitors
of all cancers. The important property of a progenitor cell
is its potential to proliferate. Even a fully differentiated
cell can become cancerous, when infected by tumorigenic
viruses, since these cancer causing viruses carry genes that
can inactivate the tumor suppessor genes and promote
cell division [78]. Therefore, neosis paradigm assumes
that cells (ESCs, GSCs or ASCs) or progenitor cells at any
stage of determination or differentiation pathway may be
subject to mutational or epimutational changes. It is pro-
posed that the mutational or epimutational damage
should be sufficient to incapacitate mitotic division and
to initiate the salvage pathway of neosis, without being
lethal to the cell. In instances where the damage is not
severe enough to inhibit successful completion of mitosis,
the initiated damage will be fixed by promotion (cell pro-
liferation) and P-neosis may be delayed until further accu-
mulation of genetic damage during the proliferative phase
[5], thus at least partially contributing to the latency of
induced neoplasms [30,31]. P-neosis is preceded by
genomic instability and followed by senescence and/or
telomere attrition. Therefore, the resultant mitotic deriva-
tives of Raju cells have the potential to become cancerous.
The following sequence of events and processes are envis-
aged to be exploited by cancer cells to survive and multi-
ply in order to avoid death.
1. Accumulation of age-dependent epimutations [160-
164] and both endogenous (inherited or through aging)
and exogenous DNA damage may cause loss of check-
point control(s) and genomic instability [63].
2. Telomere attrition may increase the GI load and induce
the senescent phase and mitotic crisis [23,58,63].
3. Some cells escape from senescence by undergoing poly-
ploidy, which confers survival value [5,6,207,208]. They
still face cell death via mitotic catastrophe [20] and neotic
catastrophe [5], while a few manage to rejuvenate the
growth of cancer by producing neotic progeny with tran-
sient stem cell properties before they die.
4. In order to survive, the cell has to eliminate the mitoti-
cally non-viable polyploid genome and produce mitoti-
cally viable genome and multiply. Neosis fulfils all these
requirements [5,6]. Delayed DNA repair
[132,133,152,153] and epigenetic modulation
[160,161,163] reduce the GI load [6] and the resultant
viable daughter genome is copied several times and is
asymmetrically distributed to the daughter Raju cells via
nuclear budding and asymmetric cytokinesis [5,6]. Since
the nuclear envelope is kept in tact during neosis, the
spindle checkpoint is not activated and this protects the
cells from death by mitotic catastrophe. The non-viable
polyploid genome of the NMC is eliminated after produc-
ing several viable Raju cells [5].
5. Since the primary Raju cells have diploid or near dip-
loid genomes derived from a non-viable polyploid
genome [5,129,132,133], neosis constitutes a parasexual
cycle of somatic reduction division, and probably incor-
porates some properties of meiosis and mitosis along with
some unique properties of neosis [6,175].
6. The important properties of P-Raju cells (progeny of P-
neosis) are genomic instability [2][5,129,227,228] and
activation of telomerase or equivalent processes
[63,64,139-141][228][229], meiotic genes [160-163],
self-renewal genes of stem cells [181-184] and multidrug
resistance genes [185,186].
7. Diploid or near diploid Raju cells of P-neosis with
genomic instability have activated telomerase and diploid
cells may inherit aneuploidy during the next S/T-neosis
[6]. Introduction of aneuploidy creates an opportunity for
breakage-fusion-bridge cycle giving rise to duplications,
deletions and gene amplification and acts as the built in
mechanism for an increase in GI load through extended
mitotic proliferative phase [63,66,67].
8. Raju cells inherit lower GI load and with transient stem
cell-like properties, display extended, but limited, MLS
and are the tumor progenitors; their EMLS is subject to tel-
omere attrition due to repetitive mitotic divisions, accom-
panied by defective differentiation. Therefore, their life
span has to be rejuvenated by S/T-neosis.
9. Thus, tumor cells appear to be in fact mortal. Tumor
cells will have to eventually die, if it were not for the proc-
ess of neosis. Some senescent cells will attain polyploidy
via endomitosis or endoreduplication, or by cell fusion
and a subset of them will escape mitotic catastrophe via S/
T-neosis, and regain extended MLS (Fig. 1).Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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10. Tumor cells are subjected to natural selection [68].
Each neotic division yields Raju cells resistant to the con-
ditions at the time of neotic event [5,6,89,132,133,216].
11. Raju cells of advanced tumors may be different from
those of the early or P-neosis, in that they may be more
malignant, with altered MLS and may undergo non-syn-
chronized S/T-neosis. Their MLS will be determined by
the nature of the mutations in their senescent, pro-apo-
totic, and longevity genes.
12. The primary event during neosis appears to be the epi-
genetic modification of the daughter cell genome result-
ing in fine tuning the gene expression profile to yield a
mitotically viable cell from the mitotically nonviable
polyploid genome, which is destined to be discarded soon
after the successful completion of neosis.
13. Neosis helps cells evade death via mitotic catastrophe,
and acts as a mechanism of cancer self-renewal by yielding
resistant Raju cells with transient stem cell properties, and
introduces heterogeneity in the tumor cell population for
natural selection to act upon.
14. Thus, neosis is dynamically involved in maintaining
the continuity of tumor cell lineage and tumor progres-
sion into malignancy. Non-synchronous occurrence of S/
T-neosis creates the illusion of the existence of Cancer
Stem Cells and the mirage of immortality of cancer cells.
Future prospects
Although preliminary, over the past few years several lab-
oratories both in Europe and in North America have
reported neosis-like events in different normal and tumor
cell types (Table 1). Studying the behavior of individual
neotic clones has revealed the significance of their central
role in cancer [5]. In almost all tumor cells in vitro and in
vivo, MN/PG cells (potential NMCs) are found and at a
given time, a minor population of NMCs will be undergo-
ing neosis in a non-synchronous fashion. Therefore, a
minor but variable fraction of Raju cells with transient
stem cell-like properties will always be found in any
tumor tissue, depending on the frequency of S/T-neosis.
Based on our observations and those of others, we have
provided preliminary evidence for a comprehensive and
pivotal role for neosis in the origin and progression of
tumors in different mammalian systems including human
primary and metastatic tumor derived cell lines in vitro
[5,6]. We have listed the properties of neosis as opposed
to those of mitosis and meiosis [Table 2 in ref. [6]]. It is
apparent that neosis is unique to the outgrowth of neo-
plastic cells from normal or established cell lines or tumor
cells under conditions of high GI load, whether it is spon-
taneous, inherited or induced by chemical, viral or physi-
cal factors. The fact that MN/PG cells are ubiquitous in
almost all types of cancers, both hematopoietic and solid
tumors, suggests that common role for neosis in cancers is
of great significance; but so far, did not receive the careful
scrutiny it deserves.
NMCs and the process of neosis may be the Achilles' heel
common to different types of cancers and therefore, may
be cancer-specific targets to develop novel anti-neotic
agents or "neosicides", which by definition could be effec-
tive in specific killing or inhibiting growth of different
tumor types, without much non-specific side effects on
normal cells. We suggest that it will be easier to target
senescent NMCs rather than targeting actively dividing
mitotic derivatives of Raju cells (equivalent of the so
called cancer stem cells, but for the difference in their ori-
gin and fate?) in order to stop the growth of tumors. In
addition, an ideal "neosicide" may be useful in preventing
the on-set of primary tumor growth in high risk individu-
als. Although there is minimal information on the molec-
ular events leading to and during neosis, the enormous
data on hand concerning karyokinesis, cytokinesis,
nuclear budding, cell cycle checkpoints, cyclins, onco-
genes, tumor suppressor genes, genomic instability, apop-
tosis, mitotic catastrophe, and molecular profiles
characterizing their alterations in different cancer types
can be exploited to formulate a rational process for under-
standing the etiology of cancer and developing rational,
effective and safe therapies against cancer.
Conclusion
We trust that the above discussion has highlighted the
drawbacks in the current concepts of the understanding of
the biology of cancer pathogenesis. Contrary to the cur-
rent belief, cancer originates via neosis and not via mito-
sis. Cancer cells are not immortal, since they also have
limited MLS and are subject to senescence and some of
them escape death by senescence due to mutations in the
senescent checkpoint pathway. Finally, cancer self-
renewal may not be because of immortal CSCs, but
because of repetitive neosis that rejuvenates cancer growth
by yielding newer populations of Raju cells, which are
more malignant or resistant to the conditions that drove
the neotic division.
Conventional non-surgical anti-cancer treatments such as
chemotherapy and radiation therapy do not distinguish
between mitotic normal and tumor cells and therefore,
have proved to be not very effective at eradicating tumor
growth and results in undesirable side effects. In addition,
these therapies are known to induce the recurrent growth
of resistant tumors probably via neosis in the place of the
originally responsive tumors [5,6,131-133]. The discovery
of neosis has identified novel cellular targets, against
which one can identify novel neosis-specific molecular
targets in order to design anti-neotic agents or neosicides.Cancer Cell International 2006, 6:25 http://www.cancerci.com/content/6/1/25
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Further, since there are no senescent cells in the normal
tissues where mitotic population is high, an ideal neosi-
cide(s) is expected to be highly specific for tumor cells and
is bound to minimize or eliminate undesirable side effects
on normal mitotic cells. It is hoped that the above discus-
sion of the significance of neosis in cancer biology will
inspire further studies on this less traveled road on the
way to better understanding cancer in order to help elim-
inate or minimize the human sufferings due to cancer.
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